<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39339965</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>RNAi-Induced Gene Silencing against Chikungunya and COVID-19: What Have We Learned So Far, and What Is the Way Forward?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1489</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091489</ELocationID><Abstract><AbstractText>RNA interference (RNAi) is a process in which small RNA molecules (such as small interfering RNAs or siRNAs) bind to specific messenger RNAs (mRNAs), leading to its degradation and inhibition of protein synthesis. Our studies have shown that RNAi can effectively silence genes involved in the replication of the Chikungunya virus (CHIKV) in cells. However, these investigations were performed only in laboratory settings and have yet to be tested in human clinical trials. Researchers need to conduct more research to determine the safety and efficacy of RNAi-based therapies as a therapeutic agent to treat viral infections. In this review, the history of evolution of siRNA as an inhibitor of protein synthesis, along with its current developments, is discussed based on our experience. Moreover, this review examines the hurdles and future implications associated with siRNA based therapeutic approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Panda</LastName><ForeName>Kingshuk</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-6533-6574</Identifier><AffiliationInfo><Affiliation>Dengue &amp; Chikungunya Group, ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alagarasu</LastName><ForeName>Kalichamy</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-1401-8589</Identifier><AffiliationInfo><Affiliation>Dengue &amp; Chikungunya Group, ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagore</LastName><ForeName>Rajarshee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dengue &amp; Chikungunya Group, ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paingankar</LastName><ForeName>Mandar</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9359-1879</Identifier><AffiliationInfo><Affiliation>Dengue &amp; Chikungunya Group, ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Satyendra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dengue &amp; Chikungunya Group, ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeengar</LastName><ForeName>Manish Kumar</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0001-6035-8643</Identifier><AffiliationInfo><Affiliation>Dengue &amp; Chikungunya Group, ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherian</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioinformatics Group, ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parashar</LastName><ForeName>Deepti</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2688-3684</Identifier><AffiliationInfo><Affiliation>Dengue &amp; Chikungunya Group, ICMR-National Institute of Virology, 20-A, Dr. Ambedkar Road, Pune 411001, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065632" MajorTopicYN="Y">Chikungunya Fever</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="Y">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002646" MajorTopicYN="Y">Chikungunya virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="Y">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chikungunya</Keyword><Keyword MajorTopicYN="N">RNA interference</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">siRNA</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339965</ArticleId><ArticleId IdType="pmc">PMC11437507</ArticleId><ArticleId IdType="doi">10.3390/v16091489</ArticleId><ArticleId IdType="pii">v16091489</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stephenson M.L., Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA. 1978;75:285–288. doi: 10.1073/pnas.75.1.285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.75.1.285</ArticleId><ArticleId IdType="pmc">PMC411231</ArticleId><ArticleId IdType="pubmed">75546</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery M.K., Xu S., Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA. 1998;95:15502–15507. doi: 10.1073/pnas.95.26.15502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.26.15502</ArticleId><ArticleId IdType="pmc">PMC28072</ArticleId><ArticleId IdType="pubmed">9860998</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbashir S.M., Martinez J., Patkaniowska A., Lendeckel W., Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 2001;20:6877–6888. doi: 10.1093/emboj/20.23.6877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.23.6877</ArticleId><ArticleId IdType="pmc">PMC125328</ArticleId><ArticleId IdType="pubmed">11726523</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh M.-C., Tassetto M., Van Rij R.P., Goic B., Gausson V., Berry B., Jacquier C., Antoniewski C., Andino R. Antiviral immunity in Drosophila requires systemic RNA interference spread. Nature. 2009;458:346–350. doi: 10.1038/nature07712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07712</ArticleId><ArticleId IdType="pmc">PMC3978076</ArticleId><ArticleId IdType="pubmed">19204732</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkhout B. RNAi-mediated antiviral immunity in mammals. Curr. Opin. Virol. 2018;32:9–14. doi: 10.1016/j.coviro.2018.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2018.07.008</ArticleId><ArticleId IdType="pubmed">30015014</ArticleId></ArticleIdList></Reference><Reference><Citation>Maillard P., Ciaudo C., Marchais A., Li Y., Jay F., Ding S., Voinnet O. Antiviral RNA interference in mammalian cells. Science. 2013;342:235–238. doi: 10.1126/science.1241930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1241930</ArticleId><ArticleId IdType="pmc">PMC3853215</ArticleId><ArticleId IdType="pubmed">24115438</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Lu J., Han Y., Fan X., Ding S.-W. RNA interference functions as an antiviral immunity mechanism in mammals. Science. 2013;342:231–234. doi: 10.1126/science.1241911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1241911</ArticleId><ArticleId IdType="pmc">PMC3875315</ArticleId><ArticleId IdType="pubmed">24115437</ArticleId></ArticleIdList></Reference><Reference><Citation>Aagaard L., Rossi J.J. RNAi therapeutics: Principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007;59:75–86. doi: 10.1016/j.addr.2007.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2007.03.005</ArticleId><ArticleId IdType="pmc">PMC1978219</ArticleId><ArticleId IdType="pubmed">17449137</ArticleId></ArticleIdList></Reference><Reference><Citation>Valinezhad Orang A., Safaralizadeh R., Kazemzadeh-Bavili M. Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int. J. Genom. 2014;2014:970607. doi: 10.1155/2014/970607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/970607</ArticleId><ArticleId IdType="pmc">PMC4142390</ArticleId><ArticleId IdType="pubmed">25180174</ArticleId></ArticleIdList></Reference><Reference><Citation>Angart P., Vocelle D., Chan C., Walton S.P. Design of siRNA therapeutics from the molecular scale. Pharmaceuticals. 2013;6:440–468. doi: 10.3390/ph6040440.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph6040440</ArticleId><ArticleId IdType="pmc">PMC3749788</ArticleId><ArticleId IdType="pubmed">23976875</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W., Jiang X., Huang L. RNA interference technology. Compr. Biotechnol. 2019:560–575. doi: 10.1016/B978-0-444-64046-8.00282-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-64046-8.00282-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvam C., Mutisya D., Prakash S., Ranganna K., Thilagavathi R. Therapeutic potential of chemically modified si RNA: Recent trends. Chem. Biol. Drug Des. 2017;90:665–678. doi: 10.1111/cbdd.12993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cbdd.12993</ArticleId><ArticleId IdType="pmc">PMC5935465</ArticleId><ArticleId IdType="pubmed">28378934</ArticleId></ArticleIdList></Reference><Reference><Citation>Urits I., Swanson D., Swett M.C., Patel A., Berardino K., Amgalan A., Berger A.A., Kassem H., Kaye A.D., Viswanath O. A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol. Ther. 2020;9:301–315. doi: 10.1007/s40120-020-00208-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40120-020-00208-1</ArticleId><ArticleId IdType="pmc">PMC7606409</ArticleId><ArticleId IdType="pubmed">32785879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci A., Ventura P. Givosiran for the treatment of acute hepatic porphyria. Expert Rev. Clin. Pharmacol. 2022;15:383–393. doi: 10.1080/17512433.2022.2075848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2022.2075848</ArticleId><ArticleId IdType="pubmed">35531651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristen A.V., Ajroud-Driss S., Conceição I., Gorevic P., Kyriakides T., Obici L. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener. Dis. Manag. 2019;9:5–23. doi: 10.2217/nmt-2018-0033.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt-2018-0033</ArticleId><ArticleId IdType="pubmed">30480471</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott L.J. Givosiran: First approval. Drugs. 2020;80:335–339. doi: 10.1007/s40265-020-01269-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01269-0</ArticleId><ArticleId IdType="pubmed">32034693</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott L.J., Keam S.J. Lumasiran: First approval. Drugs. 2021;81:277–282. doi: 10.1007/s40265-020-01463-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01463-0</ArticleId><ArticleId IdType="pubmed">33405070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray K.K., Wright R.S., Kallend D., Koenig W., Leiter L.A., Raal F.J., Bisch J.A., Richardson T., Jaros M., Wijngaard P.L. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N. Engl. J. Med. 2020;382:1507–1519. doi: 10.1056/NEJMoa1912387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912387</ArticleId><ArticleId IdType="pubmed">32187462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. FDA approves fifth RNAi drug-Alnylam’ next-gen hATTR treatment. Nat. Rev. Drug Discov. 2022;21:548–549.</Citation><ArticleIdList><ArticleId IdType="pubmed">35794463</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed Y.Y. Nedosiran: First approval. Drugs. 2023;83:1729–1733. doi: 10.1007/s40265-023-01976-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-023-01976-4</ArticleId><ArticleId IdType="pmc">PMC10803381</ArticleId><ArticleId IdType="pubmed">38060091</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbashir S.M., Lendeckel W., Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev. 2001;15:188–200. doi: 10.1101/gad.862301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.862301</ArticleId><ArticleId IdType="pmc">PMC312613</ArticleId><ArticleId IdType="pubmed">11157775</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt A.J., MacRae I.J. The RNA-induced silencing complex: A versatile gene-silencing machine. J. Biol. Chem. 2009;284:17897–17901. doi: 10.1074/jbc.R900012200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R900012200</ArticleId><ArticleId IdType="pmc">PMC2709356</ArticleId><ArticleId IdType="pubmed">19342379</ArticleId></ArticleIdList></Reference><Reference><Citation>Dana H., Chalbatani G.M., Mahmoodzadeh H., Karimloo R., Rezaiean O., Moradzadeh A., Mehmandoost N., Moazzen F., Mazraeh A., Marmari V. Molecular mechanisms and biological functions of siRNA. Int. J. Biomed. Sci. IJBS. 2017;13:48. doi: 10.59566/IJBS.2017.13048.</Citation><ArticleIdList><ArticleId IdType="doi">10.59566/IJBS.2017.13048</ArticleId><ArticleId IdType="pmc">PMC5542916</ArticleId><ArticleId IdType="pubmed">28824341</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheu-Gruttadauria J., MacRae I.J. Structural foundations of RNA silencing by argonaute. J. Mol. Biol. 2017;429:2619–2639. doi: 10.1016/j.jmb.2017.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2017.07.018</ArticleId><ArticleId IdType="pmc">PMC5576611</ArticleId><ArticleId IdType="pubmed">28757069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ui-Tei K., Naito Y., Takahashi F., Haraguchi T., Ohki-Hamazaki H., Juni A., Ueda R., Saigo K. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 2004;32:936–948. doi: 10.1093/nar/gkh247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh247</ArticleId><ArticleId IdType="pmc">PMC373388</ArticleId><ArticleId IdType="pubmed">14769950</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhr E., Zare F., Teimoori-Toolabi L. Precise and efficient siRNA design: A key point in competent gene silencing. Cancer Gene Ther. 2016;23:73–82. doi: 10.1038/cgt.2016.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cgt.2016.4</ArticleId><ArticleId IdType="pubmed">26987292</ArticleId></ArticleIdList></Reference><Reference><Citation>Mysara M., Garibaldi J.M., ElHefnawi M. MysiRNA-designer: A workflow for efficient siRNA design. PLoS ONE. 2011;6:e25642. doi: 10.1371/journal.pone.0025642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025642</ArticleId><ArticleId IdType="pmc">PMC3202522</ArticleId><ArticleId IdType="pubmed">22046244</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohrab S.S., El-Kafrawy S.A., Mirza Z., Kamal M.A., Azhar E.I. Design and delivery of therapeutic siRNAs: Application to MERS-coronavirus. Curr. Pharm. Des. 2018;24:62–77. doi: 10.2174/1381612823666171109112307.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612823666171109112307</ArticleId><ArticleId IdType="pubmed">29119921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucharz E.J., Cebula-Byrska I. Chikungunya fever. Eur. J. Intern. Med. 2012;23:325–329. doi: 10.1016/j.ejim.2012.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2012.01.009</ArticleId><ArticleId IdType="pubmed">22560378</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lima Cavalcanti T.Y.V., Pereira M.R., de Paula S.O., Franca R.F.d.O. A review on chikungunya virus epidemiology, pathogenesis and current vaccine development. Viruses. 2022;14:969. doi: 10.3390/v14050969.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14050969</ArticleId><ArticleId IdType="pmc">PMC9147731</ArticleId><ArticleId IdType="pubmed">35632709</ArticleId></ArticleIdList></Reference><Reference><Citation>Basurko C., Matheus S., Hildéral H., Everhard S., Restrepo M., Cuadro-Alvarez E., Lambert V., Boukhari R., Duvernois J.-P., Favre A. Estimating the risk of vertical transmission of dengue: A prospective study. Am. J. Trop. Med. Hyg. 2018;98:1826. doi: 10.4269/ajtmh.16-0794.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.16-0794</ArticleId><ArticleId IdType="pmc">PMC6086150</ArticleId><ArticleId IdType="pubmed">29692297</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss J.H., Strauss E.G. The alphaviruses: Gene expression, replication, and evolution. Microbiol. Rev. 1994;58:491–562. doi: 10.1128/mr.58.3.491-562.1994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mr.58.3.491-562.1994</ArticleId><ArticleId IdType="pmc">PMC372977</ArticleId><ArticleId IdType="pubmed">7968923</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal M., Berhanu G., Desalegn C., Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): An update. Cureus. 2020;12:e7423. doi: 10.7759/cureus.7423.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.7423</ArticleId><ArticleId IdType="pmc">PMC7182166</ArticleId><ArticleId IdType="pubmed">32337143</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Rohaimi A.H., Al Otaibi F. Novel SARS-CoV-2 outbreak and COVID-19 disease; a systemic review on the global pandemic. Genes Dis. 2020;7:491–501. doi: 10.1016/j.gendis.2020.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2020.06.004</ArticleId><ArticleId IdType="pmc">PMC7729096</ArticleId><ArticleId IdType="pubmed">33335956</ArticleId></ArticleIdList></Reference><Reference><Citation>Naqvi A.A.T., Fatima K., Mohammad T., Fatima U., Singh I.K., Singh A., Atif S.M., Hariprasad G., Hasan G.M., Hassan M.I. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim. Biophys. Acta BBA Mol. Basis Dis. 2020;1866:165878. doi: 10.1016/j.bbadis.2020.165878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2020.165878</ArticleId><ArticleId IdType="pmc">PMC7293463</ArticleId><ArticleId IdType="pubmed">32544429</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash P.K., Tiwari M., Santhosh S., Parida M., Rao P.L. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem. Biophys. Res. Commun. 2008;376:718–722. doi: 10.1016/j.bbrc.2008.09.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2008.09.040</ArticleId><ArticleId IdType="pubmed">18805396</ArticleId></ArticleIdList></Reference><Reference><Citation>Parashar D., Paingankar M.S., Kumar S., Gokhale M.D., Sudeep A., Shinde S.B., Arankalle V. Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus. PLoS Neglected Trop. Dis. 2013;7:e2405. doi: 10.1371/journal.pntd.0002405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002405</ArticleId><ArticleId IdType="pmc">PMC3764232</ArticleId><ArticleId IdType="pubmed">24040429</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeengar M.K., Kurakula M., Patil P., More A., Sistla R., Parashar D. Effect of cationic lipid nanoparticle loaded siRNA with stearylamine against chikungunya virus. Molecules. 2022;27:1170. doi: 10.3390/molecules27041170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27041170</ArticleId><ArticleId IdType="pmc">PMC8877324</ArticleId><ArticleId IdType="pubmed">35208958</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B., Yang Z., Zhu Y., Xia Y. Zeolitic imidazolate framework materials: Recent progress in synthesis and applications. J. Mater. Chem. A. 2014;2:16811–16831. doi: 10.1039/C4TA02984D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C4TA02984D</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagore R., Alagarasu K., Patil P., Pyreddy S., Polash S.A., Kakade M., Shukla R., Parashar D. Targeted in vitro gene silencing of E2 and nsP1 genes of chikungunya virus by biocompatible zeolitic imidazolate framework. Front. Bioeng. Biotechnol. 2022;10:1003448. doi: 10.3389/fbioe.2022.1003448.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2022.1003448</ArticleId><ArticleId IdType="pmc">PMC9806579</ArticleId><ArticleId IdType="pubmed">36601387</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury U.F., Shohan M.U.S., Hoque K.I., Beg M.A., Siam M.K.S., Moni M.A. A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2. Genomics. 2021;113:331–343. doi: 10.1016/j.ygeno.2020.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2020.12.021</ArticleId><ArticleId IdType="pmc">PMC7832576</ArticleId><ArticleId IdType="pubmed">33321203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Feng P., Liu K., Wu M., Lin H. Computational identification of small interfering RNA targets in SARS-CoV-2. Virol. Sin. 2020;35:359–361. doi: 10.1007/s12250-020-00221-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00221-6</ArticleId><ArticleId IdType="pmc">PMC7157830</ArticleId><ArticleId IdType="pubmed">32297156</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda K., Alagarasu K., Cherian S.S., Parashar D. Prediction of potential small interfering RNA molecules for silencing of the spike gene of SARS-CoV-2. Indian J. Med. Res. 2021;153:182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184069</ArticleId><ArticleId IdType="pubmed">33818475</ArticleId></ArticleIdList></Reference><Reference><Citation>Madanagopal P., Muthukumar H., Thiruvengadam K. Computational study and design of effective siRNAs to silence structural proteins associated genes of Indian SARS-CoV-2 strains. Comput. Biol. Chem. 2022;98:107687. doi: 10.1016/j.compbiolchem.2022.107687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiolchem.2022.107687</ArticleId><ArticleId IdType="pmc">PMC9052778</ArticleId><ArticleId IdType="pubmed">35537364</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolksdorf B., Nie C., Niemeyer D., Röhrs V., Berg J., Lauster D., Adler J.M., Haag R., Trimpert J., Kaufer B. Inhibition of SARS-CoV-2 replication by a small interfering RNA targeting the leader sequence. Viruses. 2021;13:2030. doi: 10.3390/v13102030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13102030</ArticleId><ArticleId IdType="pmc">PMC8539227</ArticleId><ArticleId IdType="pubmed">34696460</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohrab S.S., El-Kafrawy S.A., Azhar E.I. Effect of insilico predicted and designed potential siRNAs on inhibition of SARS-CoV-2 in HEK-293 cells. J. King Saud Univ.-Sci. 2022;34:101965. doi: 10.1016/j.jksus.2022.101965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jksus.2022.101965</ArticleId><ArticleId IdType="pmc">PMC8925144</ArticleId><ArticleId IdType="pubmed">35313445</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohani N., Moughari F.A., Eslahchi C. DisCoVering potential candidates of RNAi-based therapy for COVID-19 using computational methods. PeerJ. 2021;9:e10505. doi: 10.7717/peerj.10505.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.10505</ArticleId><ArticleId IdType="pmc">PMC7919535</ArticleId><ArticleId IdType="pubmed">33680575</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan S., Choudhary S., Kumar P., Tomar S. Antiviral strategies targeting host factors and mechanisms obliging+ ssRNA viral pathogens. Bioorganic Med. Chem. 2021;46:116356. doi: 10.1016/j.bmc.2021.116356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2021.116356</ArticleId><ArticleId IdType="pmc">PMC8349405</ArticleId><ArticleId IdType="pubmed">34416512</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijay K. Toll-like receptors in immunity and inflammatory diseases: Past, present, and future. Int. Immunopharmacol. 2018;59:391–412. doi: 10.1016/j.intimp.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.03.002</ArticleId><ArticleId IdType="pmc">PMC7106078</ArticleId><ArticleId IdType="pubmed">29730580</ArticleId></ArticleIdList></Reference><Reference><Citation>Järver P., Dondalska A., Poux C., Sandberg A., Bergenstråhle J., Sköld A.E., Dereuddre-Bosquet N., Martinon F., Pålsson S., Zaghloul E. Single-stranded nucleic acids regulate TLR3/4/7 activation through interference with clathrin-mediated endocytosis. Sci. Rep. 2018;8:15841. doi: 10.1038/s41598-018-33960-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-33960-4</ArticleId><ArticleId IdType="pmc">PMC6203749</ArticleId><ArticleId IdType="pubmed">30367171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjith-Kumar C., Duffy K., Jordan J., Eaton-Bassiri A., Vaughan R., Hoose S.A., Lamb R.J., Sarisky R., Kao C.C. Single-stranded oligonucleotides can inhibit cytokine production induced by human toll-like receptor 3. Mol. Cell. Biol. 2008;28:4507–4519. doi: 10.1128/MCB.00308-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00308-08</ArticleId><ArticleId IdType="pmc">PMC2447120</ArticleId><ArticleId IdType="pubmed">18490443</ArticleId></ArticleIdList></Reference><Reference><Citation>Sköld A.E., Hasan M., Vargas L., Saidi H., Bosquet N., Le Grand R., Smith C.E., Spetz A.-L. Single-stranded DNA oligonucleotides inhibit TLR3-mediated responses in human monocyte-derived dendritic cells and in vivo in cynomolgus macaques. Blood J. Am. Soc. Hematol. 2012;120:768–777. doi: 10.1182/blood-2011-12-397778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-12-397778</ArticleId><ArticleId IdType="pubmed">22700721</ArticleId></ArticleIdList></Reference><Reference><Citation>Pålsson S.A., Dondalska A., Bergenstråhle J., Rolfes C., Björk A., Sedano L., Power U.F., Rameix-Welti M.-A., Lundeberg J., Wahren-Herlenius M. Single-stranded oligonucleotide-mediated inhibition of respiratory syncytial virus infection. Front. Immunol. 2020;11:580547. doi: 10.3389/fimmu.2020.580547.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.580547</ArticleId><ArticleId IdType="pmc">PMC7752805</ArticleId><ArticleId IdType="pubmed">33363532</ArticleId></ArticleIdList></Reference><Reference><Citation>Pålsson S.A., Sekar V., Kutter C., Friedländer M.R., Spetz A.-L. Inhibition of respiratory syncytial virus infection by small non-coding RNA fragments. Int. J. Mol. Sci. 2022;23:5990. doi: 10.3390/ijms23115990.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23115990</ArticleId><ArticleId IdType="pmc">PMC9180592</ArticleId><ArticleId IdType="pubmed">35682669</ArticleId></ArticleIdList></Reference><Reference><Citation>Suvarna V. Phase IV of drug development. Perspect. Clin. Res. 2010;1:57. doi: 10.4103/2229-3485.71852.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2229-3485.71852</ArticleId><ArticleId IdType="pmc">PMC3148611</ArticleId><ArticleId IdType="pubmed">21829783</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M.M., Bahal R., Rasmussen T.P., Manautou J.E., Zhong X.-B. The growth of siRNA-based therapeutics: Updated clinical studies. Biochem. Pharmacol. 2021;189:114432. doi: 10.1016/j.bcp.2021.114432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2021.114432</ArticleId><ArticleId IdType="pmc">PMC8187268</ArticleId><ArticleId IdType="pubmed">33513339</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVincenzo J., Lambkin-Williams R., Wilkinson T., Cehelsky J., Nochur S., Walsh E., Meyers R., Gollob J., Vaishnaw A. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. USA. 2010;107:8800–8805. doi: 10.1073/pnas.0912186107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912186107</ArticleId><ArticleId IdType="pmc">PMC2889365</ArticleId><ArticleId IdType="pubmed">20421463</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghamiri S., Jafarpour A., Gomari M.M., Ghorbani J., Rajabibazl M., Payandeh Z. siRNA nanotherapeutics: A promising strategy for anti-HBV therapy. IET Nanobiotechnol. 2019;13:457–463. doi: 10.1049/iet-nbt.2018.5286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1049/iet-nbt.2018.5286</ArticleId></ArticleIdList></Reference><Reference><Citation>Thi E.P., Mire C.E., Lee A.C., Geisbert J.B., Zhou J.Z., Agans K.N., Snead N.M., Deer D.J., Barnard T.R., Fenton K.A. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature. 2015;521:362–365. doi: 10.1038/nature14442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14442</ArticleId><ArticleId IdType="pmc">PMC4467030</ArticleId><ArticleId IdType="pubmed">25901685</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamora M.R., Budev M., Rolfe M., Gottlieb J., Humar A., DeVincenzo J., Vaishnaw A., Cehelsky J., Albert G., Nochur S. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 2011;183:531–538. doi: 10.1164/rccm.201003-0422OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201003-0422OC</ArticleId><ArticleId IdType="pubmed">20851929</ArticleId></ArticleIdList></Reference><Reference><Citation>Gane E., Lim Y.-S., Kim J.B., Jadhav V., Shen L., Bakardjiev A.I., Huang S.A., Cathcart A.L., Lempp F.A., Janas M.M. Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for Chronic Hepatitis B: Results From Randomized Clinical Trials. J. Hepatol. 2023;79:924–932. doi: 10.1016/j.jhep.2023.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2023.05.023</ArticleId><ArticleId IdType="pubmed">37290591</ArticleId></ArticleIdList></Reference><Reference><Citation>Symonds G., Bartlett J.S., Kiem H.-P., Tsie M., Breton L. Cell-delivered entry inhibitors for HIV-1: CCR5 downregulation and blocking virus/membrane fusion in defending the host cell population. AIDS Patient Care STDs. 2016;30:545–550. doi: 10.1089/apc.2016.0245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/apc.2016.0245</ArticleId><ArticleId IdType="pubmed">27905841</ArticleId></ArticleIdList></Reference><Reference><Citation>DiGiusto D.L., Krishnan A., Li L., Li H., Li S., Rao A., Mi S., Yam P., Stinson S., Kalos M. RNA-based gene therapy for HIV with lentiviral vector–modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2010;2:36ra43. doi: 10.1126/scitranslmed.3000931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3000931</ArticleId><ArticleId IdType="pmc">PMC3130552</ArticleId><ArticleId IdType="pubmed">20555022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft C.S., Hewlett A.L., Koepsell S., Winkler A.M., Kratochvil C.J., Larson L., Varkey J.B., Mehta A.K., Lyon III G.M., Friedman-Moraco R.J. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin. Infect. Dis. 2015;61:496–502. doi: 10.1093/cid/civ334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ334</ArticleId><ArticleId IdType="pmc">PMC4542597</ArticleId><ArticleId IdType="pubmed">25904375</ArticleId></ArticleIdList></Reference><Reference><Citation>Haussecker D. Current issues of RNAi therapeutics delivery and development. J. Control Release. 2014;195:49–54. doi: 10.1016/j.jconrel.2014.07.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2014.07.056</ArticleId><ArticleId IdType="pubmed">25111131</ArticleId></ArticleIdList></Reference><Reference><Citation>Saw P.E., Song E.-W. siRNA therapeutics: A clinical reality. Sci. China Life Sci. 2020;63:485–500. doi: 10.1007/s11427-018-9438-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-018-9438-y</ArticleId><ArticleId IdType="pubmed">31054052</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshaer W., Zureigat H., Al Karaki A., Al-Kadash A., Gharaibeh L., Ma’mon M.H., Aljabali A.A., Awidi A. siRNA: Mechanism of action, challenges, and therapeutic approaches. Eur. J. Pharmacol. 2021;905:174178. doi: 10.1016/j.ejphar.2021.174178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.174178</ArticleId><ArticleId IdType="pubmed">34044011</ArticleId></ArticleIdList></Reference><Reference><Citation>Supramaniam A., Tayyar Y., Clarke D.T., Kelly G., Acharya D., Morris K.V., McMillan N.A., Idris A. Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection. J. Microbiol. Immunol. Infect. 2023;56:516–525. doi: 10.1016/j.jmii.2023.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2023.02.010</ArticleId><ArticleId IdType="pmc">PMC9991324</ArticleId><ArticleId IdType="pubmed">36934064</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleavey G.F., Watts J.K., Damha M.J. Chemical modification of siRNA. Curr. Protoc. Nucleic Acid Chem. 2009;39:16.3.1–16.3.22. doi: 10.1002/0471142700.nc1603s39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471142700.nc1603s39</ArticleId><ArticleId IdType="pubmed">20013783</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja M.A.G., Katas H., Amjad M.W. Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA. Asian J. Pharm. Sci. 2019;14:497–510. doi: 10.1016/j.ajps.2018.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajps.2018.12.005</ArticleId><ArticleId IdType="pmc">PMC7032099</ArticleId><ArticleId IdType="pubmed">32104477</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts J.K., Choubdar N., Sadalapure K., Robert F., Wahba A.S., Pelletier J., Mario Pinto B., Damha M.J. 2′-Fluoro-4′-thioarabino-modified oligonucleotides: Conformational switches linked to siRNA activity. Nucleic Acids Res. 2007;35:1441–1451. doi: 10.1093/nar/gkl1153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkl1153</ArticleId><ArticleId IdType="pmc">PMC1865065</ArticleId><ArticleId IdType="pubmed">17284457</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Wang X., Zhou X., Wang J., Guan Z., Yang Z. Optimization in Chemical Modification of Single-Stranded siRNA Encapsulated by Neutral Cytidinyl/Cationic Lipids. Front. Chem. 2022;10:843181. doi: 10.3389/fchem.2022.843181.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2022.843181</ArticleId><ArticleId IdType="pmc">PMC8957067</ArticleId><ArticleId IdType="pubmed">35345539</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Wang J., Jiang K., Chung E.J. Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions. J. Control Release. 2021;334:127–137. doi: 10.1016/j.jconrel.2021.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2021.04.016</ArticleId><ArticleId IdType="pmc">PMC8192458</ArticleId><ArticleId IdType="pubmed">33892054</ArticleId></ArticleIdList></Reference><Reference><Citation>Subhan M.A., Attia S.A., Torchilin V.P. Advances in siRNA delivery strategies for the treatment of MDR cancer. Life Sci. 2021;274:119337. doi: 10.1016/j.lfs.2021.119337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.119337</ArticleId><ArticleId IdType="pubmed">33713664</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhr O.B., Coelho T., Buades J., Pouget J., Conceicao I., Berk J., Schmidt H., Waddington-Cruz M., Campistol J.M., Bettencourt B.R. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multi-dose study. Orphanet J. Rare Dis. 2015;10:1–9. doi: 10.1186/s13023-015-0326-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-015-0326-6</ArticleId><ArticleId IdType="pmc">PMC4559363</ArticleId><ArticleId IdType="pubmed">26338094</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen H., Sun T., Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther. 2012;19:367–373. doi: 10.1038/cgt.2012.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cgt.2012.22</ArticleId><ArticleId IdType="pmc">PMC3842228</ArticleId><ArticleId IdType="pubmed">22555511</ArticleId></ArticleIdList></Reference><Reference><Citation>Springer A.D., Dowdy S.F. GalNAc-siRNA conjugates: Leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28:109–118. doi: 10.1089/nat.2018.0736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2018.0736</ArticleId><ArticleId IdType="pmc">PMC5994659</ArticleId><ArticleId IdType="pubmed">29792572</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck D., Mytilinaiou M.G., Lapin S.V., Reinhold D., Conrad K. Asialoglycoprotein receptor (ASGPR): A peculiar target of liver-specific autoimmunity. Autoimmun. Highlights. 2012;3:119–125. doi: 10.1007/s13317-012-0041-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13317-012-0041-4</ArticleId><ArticleId IdType="pmc">PMC4389076</ArticleId><ArticleId IdType="pubmed">26000135</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>